The fintech firm is the worst-performing stock in the S&P 500 this year. Is now the time to swoop in?
Anthony Summers
Anthony Summers is the Director of Trading for The Oxford Club and a contributing writer across several of its publications, including the premium monthly newsletter The Oxford Income Letter and the e-letter Wealthy Retirement. He is the author of Wealthy Retirement’s weekly Value Meter column, which focuses on identifying undervalued investment opportunities through a disciplined, long-term lens.
With over a decade of experience in the financial markets, Anthony specializes in developing profitable short- and long-term strategies across stocks, bonds, and options. His trademark approach − which he calls “conservatively aggressive” − blends risk-conscious discipline with opportunistic thinking.
His research has helped guide thousands of self-directed investors toward smarter, more confident financial decisions.
Beyond his professional work, Anthony is a devoted Christian, husband, and father. When he’s not researching or writing, you’ll likely find him reading, running, or enjoying a quiet evening with a fine cigar and a well-aged dram of single malt.
Anthony Summers
Anthony Summers is the Director of Trading for The Oxford Club and a contributing writer across several of its publications, including the premium monthly newsletter The Oxford Income Letter and the e-letter Wealthy Retirement. He is the author of Wealthy Retirement’s weekly Value Meter column, which focuses on identifying undervalued investment opportunities through a disciplined, long-term lens.
With over a decade of experience in the financial markets, Anthony specializes in developing profitable short- and long-term strategies across stocks, bonds, and options. His trademark approach − which he calls “conservatively aggressive” − blends risk-conscious discipline with opportunistic thinking.
His research has helped guide thousands of self-directed investors toward smarter, more confident financial decisions.
Beyond his professional work, Anthony is a devoted Christian, husband, and father. When he’s not researching or writing, you’ll likely find him reading, running, or enjoying a quiet evening with a fine cigar and a well-aged dram of single malt.
-
-
Here’s a way to get exposure to gold without betting the farm.
-
The Value Meter
Stoke Therapeutics: A Biotech on the Verge of a Breakthrough
Friday, October 17, 2025The stock is up almost 6X since April – can it keep it up?
-
In a market full of noise, this is the one metric that can’t be faked.
-
With shares running hot again, is NFLX still a good buy?
-
Is it worth it? Find out in this edition of The Value Meter.
-
The company is involved in both gold and rare earths – a fascinating combo.
-
This company could play a key role in cutting into China’s dominance.
-
Reports of the company’s demise have been greatly exaggerated.
-
It pays to look where others aren’t.